SAN FRANCISCO, April 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Zoetis Inc. (NYSE: ZTS) investors who suffered substantial losses to submit your losses now and persons with knowledge who may be able to assist the investigation to contact its attorneys.
| Visit: www.hbsslaw.com/investor-fraud/ZTS | |
| Contact An Attorney Now: | ZTS@hbsslaw.com |
| 844-916-0895 | |
Zoetis Inc. (ZTS) Investigation:
On Apr. 12, 2024, the price of Zoetis shares fell $12.75, or nearly 8%, after the WSJ published “What Killed Their Pets? Owners Blame Meds, but Vets Aren’t Sure.”
The WSJ’s article focuses on Zoetis’ Librela and Solensia, therapies intended to relieve painful canine and feline osteoarthritis, respectively. In the past, the products have been important revenue contributors to Zoetis’ companion animal products business and the company has said it expects its osteoarthritis pain franchise to reach more than $1 billion in peak sales.
But, the WSJ report may have brought Zoetis’ peak sales goal into question due to reports that pet owners who have blamed the drugs for sickening their animals, some of whom have died.
The WSJ further reported that “[h]ealth regulators in the U.S. and Europe -- which have received thousands of reports of side effects – are conducting reviews[]” and “Wall Street analysts have asked Zoetis about the pet owners’ complaints.”
“We are investigating whether Zoetis may have potentially put profits ahead of pet safety,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you invested in Zoetis and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »
If you’d like more information and answers to frequently asked questions about the Zoetis investigation, read more »
Whistleblowers: Persons with non-public information regarding Zoetis should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ZTS@hbsslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Reed Kathrein, 844-916-0895
